# Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

> **NCT05276570** · PHASE1,PHASE2 · COMPLETED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 127 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** ARO-RAGE
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05276570
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-29
- **Primary completion:** 2025-04-16
- **Final completion:** 2025-04-16
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05276570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05276570, "Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05276570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*